Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab + Chemotherapy vs Surgery in HNSCC
NCT05582265Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen Memorial Hospital. Started Oct 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05582265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05582265.